Perrigo launches generic Clobex spray

DUBLIN — Perrigo on Monday announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex spray, 0.05%. Perrigo was the first generic filer against this product and it is entitled to 180 days of generic exclusivity. The launch date was agreed upon in a litigation settlement between Perrigo and Galderma Labs.

 

Clobetasol propionate spray, 0.05% is indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area in adults 18 years of age or older. Fifty-two week sales of the product were approximately $100 million, according to IMS Health.

 

"This is another example of our Rx team's commitment to launching difficult to manufacture products," said Joseph Papa, Perrigo chairman, president and CEO. "We are excited to market this product and are dedicated to making quality healthcare more affordable for consumers around the globe."